MMP-13 active protein

MMP-13 (catalytic domain) (human), (recombinant)

Cat. Num. AAA566595

• Purity: >=95% (SDS-PAGE); Purified by multi-step chromatography
• Synonyms: MMP-13; MMP-13 (catalytic domain) (human); (recombinant); MMP-13 active protein

• Host: E Coli
• Purity/Purification: >=95% (SDS-PAGE); Purified by multi-step chromatography
• Form/Format: Liquid. In 50mM TRIS, 5mM CaCl2, 300mM NaCl, 20uM ZnCl2, 0.5% Brij-35, and 30% glycerol

• Source Note: Active Matrix Metalloproteinase-13 (MMP-13, collagenase-3) catalytic domain from human cDNA. The enzyme consists of the catalytic domain of human MMP-13 (Tyr104-Asn274) with a C-terminal purification tag. This represents a naturally-occurring active form of MMP-13 which lacks the C-terminal hemopexin domain. MMPs lacking this domain cannot cleave native collagens; however, activity toward other targets such as gelatin, casein, or peptide substrates is unaffected
• Activity: Preincubation of MMP-13 catalytic domain at 13nM with the broad-spectrum inhibitor GM6001 at 20nM for 1 hour completely inhibits enzymatic activity
• Specific Activity: >=100U/ug. One U=100 pmol/min at 37 degree C using the colorimetric thiopeptolide Ac-Pro-Leu-Gly-S-Leu-Leu-Gly-OEt (100uM) as substrate
• Dry Ice Shipment: Extra charge fee may add to your shipping cost as dry ice is required to ship this product.
• Preparation and Storage: For long term storage, store at -80 degree C; Shipping: Shipped on Dry Ice

Product Categories/Family for MMP-13 active protein

Cellular Analysis; Cell Organelles & Structures; Proteostasis; Proteolysis & Protein Degradation

NCBI and Uniprot Product Information

• UniProt Accession #: P45452
• Molecular Weight: 204kDa
• UniProt Protein Name: Collagenase 3
• UniProt Gene Name: MMP13
• UniProt Synonym Gene Names: MMP-13
• UniProt Entry Name: MMP13_HUMAN

Uniprot Description

MMP13: Degrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process. Defects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO). A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age. Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1). Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia. Belongs to the peptidase M10A family.

Protein type: Secreted; Secreted, signal peptide; EC 3.4.24.-; Protease

Chromosomal Location of Human Ortholog: 11q22.3

Cellular Component: proteinaceous extracellular matrix; extracellular space; extracellular region

Molecular Function: collagen binding; zinc ion binding; metalloendopeptidase activity; calcium ion binding

Biological Process: collagen catabolic process; extracellular matrix disassembly; extracellular matrix organization and biogenesis; cellular protein metabolic process; proteolysis; bone mineralization; endochondral ossification

Disease: Spondyloepimetaphyseal Dysplasia, Missouri Type